Lv3
356 积分 2024-05-28 加入
Reformation of a Clinical Anti-Drug Antibody Assay to Enable the Immunogenicity Assessment of a Bispecific Antibody Biotherapeutic
1天前
待确认
Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points
2天前
已完结
Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
2天前
已完结
Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
2天前
已完结
Cut Point in Immunogenicity Testing: A Flawed Concept We Can Live Without
2天前
已完结
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays
2天前
已完结
Best practices in the application of parallelism for biomarker assay validation
7天前
已完结
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
2个月前
已完结
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
2个月前
已完结
Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors
3个月前
已完结
皖公网安备34019202002308
